Valuation
- Market cap
- 39,367,000
- Revenue TTM
- $200,000
- Net income TTM
- $-1,110,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -555.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,000
- Avg volume
- 19,610
- Day's range
- $0.57 – $0.58
- Shares out
- 67,933,000
- Stochastic %K
- 37%
- Beta
- 1.47
- Analysts
- —
- Price target
- $3.50
Company profile
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury v...
Show more
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 647-428-7031
- Website
- https://www.archbiopartners.com
- Address
- 545 King Street West, Toronto, Canada
Latest news
No headlines yet.
